Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Valneva ( (VALN) ).
On February 13, 2026, Valneva reported that the UK’s Commission on Human Medicines has updated its recommendations for the company’s single-dose chikungunya vaccine IXCHIQ, leading to revised prescribing information. The update introduces restrictions for people over 60, for patients with specified health conditions, and clarifies timing before travel, following serious adverse event reports mainly among elderly individuals with significant comorbidities during an outbreak campaign on La Réunion.
The UK medicines regulator confirmed that IXCHIQ’s benefit–risk profile remains favorable for individuals aged 18 to 59 at risk of chikungunya infection without contraindicated conditions. The move underscores ongoing regulatory scrutiny of novel travel vaccines while allowing Valneva to continue commercializing IXCHIQ for a key adult segment, as the company stresses its commitment to high safety standards and continued post-marketing monitoring in coordination with health authorities.
The most recent analyst rating on (VALN) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s overall stock score reflects significant financial challenges, including negative profitability and cash flow issues. While technical indicators show neutral momentum, and the earnings call highlighted some positive developments, the company’s high leverage and ongoing losses weigh heavily on the score. Promising clinical advancements provide potential for future growth but are not enough to offset current financial concerns.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The group focuses on targeted, first- or best-in-class solutions, currently markets three proprietary travel vaccines, and is advancing a pipeline that includes the only Lyme disease vaccine candidate in advanced clinical development with Pfizer, as well as Shigella and Zika vaccine programs.
Average Trading Volume: 18,748
Technical Sentiment Signal: Buy
Current Market Cap: $829.5M
For detailed information about VALN stock, go to TipRanks’ Stock Analysis page.